High frequency of CD4+FoxP3+ cells in HTLV-1 infection: Inverse correlation with HTLV-l-specific CTL response

Blood

Volumn 111, Issue 10, 2008, Pages 5047-5053

  Toulza, Frederic ^a   Heaps, Adrian ^a   Tanaka, Yuetsu ^b   Taylor, Graham P ^a   Bangham, Charles R M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; TAX PROTEIN; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; VIRUS LOAD; CD4+ T LYMPHOCYTE; CYTOLOGY; CYTOTOXICITY; IMMUNOLOGY; LYMPHOCYTE COUNT; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FORKHEAD TRANSCRIPTION FACTORS; HTLV-I INFECTIONS; HUMANS; LYMPHOCYTE COUNT; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 46749100265     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-118539     Document Type: Article

References (49)

1. Osame M, Usuku K, Izurno S; et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1:1031-1032.
2. Nagai M, Osarne M. Human T-cell lymphotropic virus type I and neurological diseases. J Neurovi- rol. 2003;9:228-235.
3. Albrecht B. Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev. 2002;66:396-406.
4. Ciminale V, Pavlakis GN, Derse D, Cunningham CP, Felber BK. Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: novel mRNAs and proteins produced by HTLVtype I. J Virol. 1992;66:1737-1745.
5. Hollsberg P. Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Microbiol Mol Biol Rev. 1999;63:308-333.
6. Wattel E, Cavrois M, Gessain A, Wain-Hobson S. Clonal expansion of infected cells: a way of life for HTLV-I. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1):S92-S99.
7. Cavrois M, Gessain A, Wain-Hobson S, Wattel E. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene. 1996;12:2419-2423.
8. Asquith B, MosleyAJ, HeapsA, et al. Quantification of the virus-host interaction in human T lymphotropic virus I infection. Retrovirology. 2005;2: 75.
9. Kannagi M. Harada S. Maruyama I, et al. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I- infected cells. Int Immunol. 1991;3:761-767.
10. Goon PK, Biancardi A, Fast N, et al. Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ Tcells: frequency and immunodominance hierarchy. J Infect Dis. 2004;189:2294-2298.
11. Hanon E, Hall S,TaylorGR et al. Abundant tax protein expression in GD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood. 2000;95:1386-1392.
12. Bangham CR. The immune control and cell-to- cell spread of human T-lymphotropic virus type 1. J Gen Virol. 2003;84:3177-3189.
13. Bangham CR; Osame M. Gellular immune response to HTLV-1. Oncogene. 2005;24:6035- 6046.
14. Asquith B; Zhang Y, Mosley AJ, et al. In vivo T lymphocyte dynamics in humans: the impact of human T-lymphotropic virus I infection. Proc Natl Acad Sci USA. 2007;104:8035-8040.
15. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006;24:209-226.
16. von Boehmer H. Mechanisms of suppression by suppressorTcells. Nat Immunol. 2005;6:338- 344.
17. Dittmer U, He H, Messer RJ, et al. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity. 2004;20:293-303.
18. Tsunemi S, Iwasaki T, Imado T, et al. Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS. 2005;19: 879-886.
19. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity. 2006;25: 195-201.
20. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol. 2003;3:189-198.
21. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6:331-337.
22. Cross SL, Feinberg MB, Wolf JB, Holbrook NJ, Wong-Staal F, Leonard WJ. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell. 1987;49:47-56.
23. Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. EMBO J 1986;5:2883-2888.
24. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701-1711.
25. Asquith B, MosleyAJ, Barfield A, et al. Afunctional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol. 2005;86:1515-1523.
26. Lee B, Tanaka Y, Tozawa H. Monoclonal antibody defining tax protein of human T-cell leukemia virus type-l. Tohoku J Exp Med. 1989;157:1-11.
27. Tosswill JH, Taylor GP, Clewley JP, Weber JN. Quantification of proviral DNA load in human T- cell leukaemia virus type I infections. J Virol Methods. 1998;75:21-26.
28. Nagai M, Usuku K, MatsumotoW, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4:586-593.
29. Vine AM, Heaps AG, Kaftantzi L, et al. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol. 2004;173:5121-5129.
30. Hanon E, Goon P, Taylor GP, et al. High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type l-infected peripheral blood mononuclear cells. Blood. 2001 ;98: 721-726.
31. Oh U, Grant C, Griffith C, Fugo K, Takenouchi N, Jacobson S. Reduced Foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus type 1 infection. J Infect Dis. 2006;193:1557-1566.
32. Royer-Leveau C, Mordelet E, Delebecque F, Gessain A, Charneau P, Ozden S. Efficient transfer of HTLV-1 tax gene in various primary and immortalized cells using a flap lentiviral vector. J Virol Methods. 2002;105:133-140.
33. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNAwith proviral DNA load, virus- specific CD8(+) Tcells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood. 2002;99:88-94.
34. Walker MR, Kasprowicz DJ, Gersuk VH, et al.Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest. 2003:112:1437-1443.
35. Wang J. loan-Facsinay A, van derVoort El, Huiz- ingaTW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37:129-138.
36. Yamano Y Takenouchi N. Li HC, et al. Virus-induced dysfunction of CD4+CD25+ Tcells in patients with HTLV-l-associated neuroimmunologi-cal disease. J Clin Invest. 2005;115:1361-1368.
37. Tao R. de Zoeten EF, Ozkaynak E, et al. Deacety- lase inhibition promotes the generation and function of regulatory Tcells. Nat Med. 2007; 13:1299-1307.
38. Mosley AJ, Meekings KN, McCarthy C, et al. His- tone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection. Blood. 2006;108:3801- 3807.
39. Kinter AL Horak R, Sion M, et al. CD25+ regulatory Tcells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ Tcells in vitro. AIDS Res Hum Retroviruses. 2007;23:438-450.
40. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002:2:389-400.
41. Mempel TR, Pittet MJ, Khazaie K, et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity. 2006;25:129-141.
42. Best I. Adaui V Verdonck K, et al. Proviral load and immune markers associated with human T- lymphotropic virus type 1 (HTLV-1 )-associated myelopathy/tropical spastic paraparesis (HAM/ TSP) in Peru. Clin Exp Immunol. 2006;146:226- 233.
43. Q'GarraA, Vieira P. Regulatory Tcells and mechanisms of immune system control. Nat Med. 2004;10:801-805.
44. Jeffery KJ, Usuku K, Hall SE, et al. HLAalleles determine human T-lymphotropic virus-l (HTLV-I) proviral load and the risk of HTLV-l-associated myelopathy. Proc Natl Acad Sci USA. 1999;96: 3848-3853.
45. Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol. 2000;165:7278-7284.
46. Vine AM, Witkover AD, Lloyd AL, et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-l-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2002;186:932-939.
47. Niewiesk S, Daenke S, Parker CE, et al. The trans activator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis. J Virol. 1994;68:6778-6781.
48. Kubota R, Hanada K, Furukawa Y, et al. Genetic stability of human T lymphotropic virus type I despite antiviral pressures by CTLs. J Immunol. 2007;178:5966-5972.
49. Niewiesk S, Daenke S, Parker CE, et al. Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax. J Virol. 1995;69:2649-2653.